Pharming Regains Rights To Ruconest, Seizing More Control Over Its Destiny
The European specialty pharma will pay $60m upfront to Valeant to reacquire the rights to commercialize the hereditary angioedema treatment in North America.
You may also be interested in...
Profitable Pharming Expands Ruconest Potential And Resurrects Pompe Pipeline
Dutch rare disease company Pharming talked to Scrip about turning a profit for the first time in the company’s history, finally restocking the pipeline in potentially blockbuster indications, and turning its attention back to Pompe disease after 20 years in the cold.
Deal Watch: AZ Ups mRNA Stake, Gilead's HIV Innovation, Hospira Returns Lucentis Biosimilar, Pfizer/Takeda End Distribution Deal
Deal activity over the past week saw AstraZeneca stealthily increase its commitment to mRNA player Moderna, Gilead seek innovation in HIV through an alliance with Genmab for its bispecific antibody technology, and Hospira back out of a licensing deal for Pfenex's Lucentis biosimilar, and more.
Valeant’s Higher Bid Seals The Deal With Salix, Ending Endo’s Quest
Valeant raised its offer to buy the GI specialist from $158 to $173 per share in cash; Salix’s board of directors accepted the revised offer, ending a bid by Endo to buy the company.